Lipfendra: the first daily oral PCSK9 inhibitor and how it compares with statins

The FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor for high cholesterol and heterozygous familial hypercholesterolemia. In trials, Lipfendra lowered LDL cholesterol by about 56–59% versus placebo, mainly in patients already on statins, but there’s no head‑to‑head comparison with statins yet. It can be used alongside statins or other lipid drugs when LDL remains above goal, offering a pill alternative to injectable PCSK9 inhibitors. However, it’s approved only for adults, has a stringent morning-on-empty-stomach regimen, and more cardiovascular outcomes data are still being gathered, so doctors will tailor its use to patients who need additional LDL lowering beyond maximally tolerated statin therapy.